Merck Sharpe & Dohme (MSD) are planning to open an office in Zurich next year. Around 250 employees would work here. The pharmaceutical group opted for Zurich on account of the city’s “exceptional academic and life sciences ecosystem”.

MSD sets up business in Zurich next year.


MSD is expanding within Switzerland: The pharmaceutical company, which is actually owned by the US enterprise Merck, is intending to open a new office in Zurich in January 2021. According to a press release, up to 250 employees could work out of the new location. While some employees from other group locations will be transferred to Zurich, MSD is also planning to hire new specialists as well.

The new location will primarily be focused on accelerating research, data collection and commercialization of medicines and vaccines. Moreover, the new office in Zurich will be staffed by teams working in strategic and operational roles in areas such as medical affairs, clinical development, access and marketing operations.

“We selected Zurich because of its exceptional academic and life sciences ecosystem coupled with its high stability and central European location”, comments Klaus Beck, Vice President, Medical Affairs, MSD in Switzerland. Beck then added, that the location of Zurich “provides an ideal setting for our teams to achieve scientific excellence by collaborating to develop and commercialize our inventions to improve human health around the world”.

MSD has been represented in Switzerland since 1963. Its regional hub is located in Lucerne and there are no plans in place to change this even after the new office in Zurich is opened.

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?